BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Paul Clayton Silma Subah, R. V., & Bogoda, N. (2023). Palmitoylethanolamide: A potential alternative to cannabidiol. Journal of Dietary Supplements, 20(3), 505–530. Added by: Dr. Enrique Feoli (30/11/2023, 12:11) Last edited by: Dr. Enrique Feoli (30/11/2023, 12:15) |
 |
| Resource type: Journal Article DOI: 10.1080/19390211.2021.2005733 BibTeX citation key: PaulClaytonSilmaSubah2023 View all bibliographic details  |
Categories: BioAcyl Corp, BioAcyl Corp Subcategories: Analgesia, Autacoides Creators: Bogoda, Paul Clayton Silma Subah Collection: Journal of Dietary Supplements |
Views: 3/87
|
| Abstract |
|
The endocannabinoid system (ECS) is a widespread cell signaling network that maintains homeostasis in response to endogenous and exogenous stressors. This has made the ECS an attractive therapeutic target for various disease states. The ECS is a well-known target of exogenous phytocannabinoids derived from cannabis plants, the most well characterized being Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). However, the therapeutic efficacy of cannabis products comes with a risk of toxicity and high abuse potential due to the psychoactivity of THC. CBD, on the other hand, is reported to have beneficial medicinal properties including analgesic, neuroprotective, anxiolytic, anticonvulsant, and antipsychotic activities, while apparently lacking the toxicity of THC. Nevertheless, not only is the currently available scientific data concerning CBD’s efficacy insufficient, there is also ambiguity surrounding its regulatory status and safety in humans that brings inherent risks to manufacturers. There is a demand for alternative compounds combining similar effects with a robust safety profile and regulatory approval. Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator, primarily known for its anti-inflammatory, analgesic and neuroprotective properties. It appears to have a multi-modal mechanism of action, by primarily activating the nuclear receptor PPAR-α while also potentially working through the ECS, thus targeting similar pathways as CBD. With proven efficacy in several therapeutic areas, its safety and tolerability profile and the development of formulations that maximize its bioavailability, PEA is a promising alternative to CBD.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |
| Notes |
|
PMID: 34842030
|